Work in this area, including in our lab, is focused on developing these multimodal strategies for precision diagnostics to better map the biological landscape that underpins early disease in vivo. At the same time, advances in artificial intelligence are helping to make sense of the data. Optical measurements can generate large and complex datasets, often revealing patterns that are not immediately visible. Artificial intelligence can help translate these patterns into tools that support clinical decision-making.
Towards earlier and more proactive diagnosis
Looking ahead, these approaches could help shift cancer diagnosis from reactive to proactive. Instead of waiting for symptoms to appear, clinicians could use optical tools to detect the earliest signs of change.
Routine check-ups might one day include quick, non-invasive scans to identify areas of concern in the earliest stages of cancer development. For people at higher risk, repeated measurements over time could help track subtle changes and guide decisions about when to intervene.
Turning this vision into reality will take collaboration – engineers, clinicians and cancer researchers will need to work closely together. It will also require continued investment to move technologies from the lab into clinical use. The UK is in a strong position to lead this effort. Many of the technologies are currently maturing so turning this into health impact will really depend on strengthening commercial support at universities and ensuring clear and supportive regulatory pathways.
Source link
